Chromic-P32 phosphate treatment of implanted pancreatic carcinoma: Mechanism involved

Table 1 Fourteen day-absorbed doses in tumor, tumor weight, tumor cell necrosis rate, MVD, PI and percentage of loosely arranged tumor cells to remaining tumor cells (n = 6).

Group	Injected dose(MBq)	Absorbed dose (Gy)	14 d tumorweight (g)	Tumor cell necroticrate(%)	F	SNK1	MVD2	PI
6	3.7	248.7	2.16±0.15	20	4.14	A	38.5±4.0	70
7	7.4	497.4	1.60±0.12	45	33.57	B	28.0±2.9	65
8	14.8	852.7	1.13±0.10	65	44.62	C	17.0±2.9	45
9	18.5	1147.8	0.86±0.09	70	54.93	C	8.8±1.5	20
10	29.6	2023.4	0.30±0.05	95	105.36	D	5.7±2.3	10
11	0	–	2.84±0.17	4	–	E	65.0±5.2	92

¹Variance analysis after conversion of tumor cell necrosis rate to square root in each group compared with 0 MBq group, F = 4.14-105.36, P<0.01, SNK test for cell necrosis rate: Same letter means no statistical difference of mean values among groups; differed letters mean the statistical difference among groups.

²Comparison of MVD between medication and control groups, t = 11.9-26.1, P<0.01, all with prominent differences.